Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
News|Articles|August 10, 2026
New in Narcolepsy: Pharmacology Updates
Author(s)Jessica Walters
Review the latest developments in narcolepsy treatment.
Advertisement
Advertisement
With the recent approval of orzeyful (oveporexton) for narcolepsy type 1, review the latest movements in the narcolepsy space.
Related to this article
Learn how to prevent and spot tardive dyskinesia from antipsychotics, track key risk factors, and treat symptoms with VMAT2 inhibitors.
Learn how the inhibition constant and 5-HT2A binding explain LSD effects—and why potent atypical antipsychotics may rapidly end a bad trip.
FDA hearing spotlights debates over psychedelic therapy: who administers, how to prove efficacy, and how to track safety as approvals near.
Experts dissect 10 common antidepressant myths, separating evidence from fear on efficacy, addiction, suicide risk, withdrawal, and safe tapering.
Phase 3 NEJM data show oveporexton improves wakefulness, reduces cataplexy, and boosts quality of life in narcolepsy type 1, with manageable adverse effects.
Phase 1 driving simulation finds bedtime GlyphAllo for major depressive disorder shows no next-morning driving impairment, while advancing allopregnanolone-based oral treatment development.
Review the developments in GLP-1s in 2026.
Advertisement
Advertisement